Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2026-01-20

FDA Approved: ZEPBOUND — Supplemental Application (Eli Lilly and Company)

View source ↗

Summary

FDA approved a supplemental application for ZEPBOUND (tirzepatide) submitted by Eli Lilly and Company.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ZEPBOUND (tirzepatide)

Snippet

SUPPL AP for ZEPBOUND (TIRZEPATIDE)